 |
|
Comparative Effects of Lovastatin and Niacin in Primary HypercholesterolemiaA Prospective Trial
D. Roger Illingworth, MD, PhD;
Evan A. Stein, MD, PhD;
Yale B. Mitchel, MD;
Carlos A. Dujovne, MD;
Philip H. Frost, MD;
Robert H. Knopp, MD;
Peggy Tun, MD;
Robert V. Zupkis, PhD;
Roger A. Greguski
Arch Intern Med. 1994;154(14):1586-1595.
Abstract
Background
Niacin and lovastatin are both effective drugs for the treatment of hypercholesterolemia and are among the drugs of first choice recommended by the adult treatment panel. To date, however, no studies have directly compared the lipoprotein-modifying effects and safety of lovastatin and niacin across their usual dosage range in patients with primary hypercholesterolemia.
Methods
The efficacy and safety of lovastatin and niacin were compared in a controlled, randomized, open-label study of 26 weeks' duration that was conducted at five lipid clinics. One hundred thirty-six patients with primary hypercholesterolemia participated in the study. Entry criteria were a low-density lipoprotein (LDL) cholesterol level greater than 4.37 mmol/L (160 mg/dL) with coronary heart disease and/or more than two coronary heart disease risk factors or an LDL cholesterol level greater than 5.19 mmol/L (190 mg/dL) in patients without coronary heart disease or less than two coronary heart disease risk factors. The study consisted of a 4-week diet run-in period after which eligible patients were randomly assigned to receive treatment with either lovastatin (20 mg/d) or niacin (1.5 g/d) for 10 weeks. On the basis of the LDL cholesterol response and patient tolerance, the doses were sequentially increased to 40 and 80 mg/d of lovastatin or 3 and 4.5 g/d of niacin after 10 and 18 weeks of treatment, respectively.
Results
In the two patient groups, 66% of patients treated with lovastatin and 54% of patients treated with niacin underwent full dosage titration. At all time points, lovastatin was significantly (P<.01) more effective than niacin in reducing LDL cholesterol levels (26% vs 5% at week 10, 28% vs 16% at week 18, and 32% vs 23% at week 26), whereas niacin was more effective (P<.01) in increasing high-density lipoprotein cholesterol levels (6% vs 20% at week 10, 8% vs 29% at week 18, and 7% vs 33% at week 26). Niacin reduced Lp(a) lipoprotein levels by 35% at week 26, whereas lovastatin had no effect. Cutaneous flushing was the most common side effect during treatment with niacin.
Conclusions
Lovastatin and niacin both exerted favorable dose-dependent changes on the concentrations of plasma lipids and lipoproteins. Lovastatin was more effective in reducing LDL cholesterol concentrations, whereas niacin was more effective in increasing high-density lipoprotein cholesterol concentrations and reducing the Lp(a) lipoprotein level. Lovastatin was better tolerated than niacin, in large part because of the common cutaneous side effects of niacin.
(Arch Intern Med. 1994;154:1586-1595)
Author Affiliations
From the Department of Medicine, Oregon Health Sciences University, Portland (Dr Illingworth); Medical Research Laboratories, Cincinnati, Ohio (Dr Stein); Merck Research Laboratories, Rahway, NJ (Drs Mitchel and Zuphis and Mr Greguski); Department of Medicine, University of Kansas Medical Center, Kansas City (Dr Dujovne); Department of Medicine, University of California—San Francisco (Drs Frost and Tun); and Department of Medicine, University of Washington School of Medicine, Seattle (Dr Knopp).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The facts behind niacin
Hochholzer et al.
Ther Adv Cardiovasc Dis 2011;5:227-240.
ABSTRACT
Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol
deGoma et al.
J Am Coll Cardiol 2008;51:49-55.
ABSTRACT
| FULL TEXT
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman et al.
Arch Intern Med 2004;164:1490-1500.
ABSTRACT
| FULL TEXT
Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease
Liu et al.
Clin. Chem. 2003;49:1347-1352.
ABSTRACT
| FULL TEXT
References
Circulation 2002;106:3373-3421.
FULL TEXT
Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial
Elam et al.
JAMA 2000;284:1263-1270.
ABSTRACT
| FULL TEXT
Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT
| FULL TEXT
Nicotinic Acid - The Underused Ally in the Fight against Coronary Disease
O'Keefe and Harris
European Journal of Cardiovascular Prevention & Rehabilitation 1997;4:161-163.
Elevated Lipoprotein(a) and Premature Coronary Heart Disease-Reply
Bostom
JAMA 1997;277:210-210.
ABSTRACT
Effect of Oral Estradiol on Lp(a) and Other Lipoproteins in Postmenopausal Women: A Randomized, Double-blind, Placebo-Controlled, Crossover Study
Haines et al.
Arch Intern Med 1996;156:866-872.
ABSTRACT
Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial
Stein et al.
J CARDIOVASC PHARMACOL THER 1996;1:107-116.
ABSTRACT
LOVASTATIN OR NIACIN FOR HYPERCHOLESTEROLEMIA?
JWatch General 1994;1994:2-2.
FULL TEXT
Nicotinic Acid as a Lipoprotein-Altering Agent: Therapy Directed by the Primary Physician
Probstfield and Hunninghake
Arch Intern Med 1994;154:1557-1559.
ABSTRACT
|
